Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands

Carrión-Salip,Dolors; Panosa,Clara; Menendez,Javier  A.; Puig,Teresa; Oliveras,Glòria; Pandiella,Atanasio; De Llorens,Rafael; Massaguer,Anna

doi:10.3892/ijo.2012.1509

Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands

Authors:
- Dolors Carrión-Salip
- Clara Panosa
- Javier A. Menendez
- Teresa Puig
- Glòria Oliveras
- Atanasio Pandiella
- Rafael De Llorens
- Anna Massaguer
View Affiliations

Affiliations: Biochemistry and Molecular Biology Unit, Department of Biology, University of Girona, Girona 17071, Spain, Unit of Translational Research, Catalan Institute of Oncology-Girona, Dr Josep Trueta University Hospital, Girona 17007, Spain, Department of Medical Science, Girona Institute for Biomedical Research, University of Girona, Girona 17071, Catalonia, Spain, Institute of Molecular and Cellular Biology of Cancer, University of Salamanca, Salamanca 37007, Spain
Published online on: June 6, 2012 https://doi.org/10.3892/ijo.2012.1509
Pages: 1128-1138

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The deregulation of the epidermal growth factor receptor (EGFR) pathway plays a major role in the pathogenesis of prostate cancer (PCa). However, therapies targeting EGFR have demonstrated limited effectiveness in PCa. A potential mechanism to overcome EGFR blockade in cancer cells is the autocrine activation of alternative receptors of the human EGFR (HER) family through the overexpression of the HER receptors and ligands. In the present study, we were interested in analyzing if this intrinsic resistance mechanism might contribute to the inefficacy of EGFR inhibitors in PCa. To this end, we selected two androgen-independent human prostate carcinoma cell lines (DU145 and PC3) and established DU145 erlotinib-resistant cells (DUErR). Cells were treated with three EGFR inhibitors (cetuximab, gefinitib and erlotinib) and the sensitivity to each treatment was assessed. The gene expression of the four EGFR/HER receptors and seven ligands of the HER family was analyzed by real-time PCR prior to and after each treatment. The receptors expression and activation were further characterized by flow cytometry and western blot analysis. EGFR inhibition rapidly induced enhanced gene expression of the EGF, betacellulin and neuregulin-1 ligands along with HER2, HER3 and HER4 receptors in the DU145 cells. In contrast, slight changes were observed in the PC3 cells, which are defective in the phosphatase and tensin homolog (PTEN) tumor suppressor gene. In the erlotinib-resistant DUErR cells, the expression of HER2 and HER3 was increased at mRNA and protein levels together with neuregulin-1, leading to enhanced HER3 phosphorylation and the activation of the downstream PI3K/Akt survival pathway. HER3 blockage by a monoclonal antibody restored the cytostatic activity of erlotinib in DUErR cells. Our results confirm that the overexpression and autocrine activation of HER3 play a key role in mediating the resistance to EGFR inhibitors in androgen-independent PCa cells.

View Figures

View References

1.	Zhu ML and Kyprianou N: Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 15:841–849. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Pomerantz M and Kantoff P: Advances in the treatment of prostate cancer. Annu Rev Med. 58:205–220. 2007. View Article : Google Scholar
3.	Traish AM and Morgentaler A: Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 101:1949–1956. 2009. View Article : Google Scholar
4.	Shah RB, Ghosh D and Elder JT: Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate. 66:1437–1444. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Shi F, Telesco SE, Liu Y, Radhakrishnan R and Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA. 107:7692–7697. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ and Yarden Y: Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem. 271:19029–19032. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Wilson KJ, Gilmore JL, Foley J, Lemmon MA and Riese DJ II: Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 122:1–8. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Iwamoto R, Yamazaki S, Asakura M, et al: Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA. 100:3221–3226. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Miyamoto S, Fukami T, Yagi H, Kuroki M and Yotsumoto F: Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res. 29:823–830. 2009.PubMed/NCBI
12.	Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
14.	Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Baselga J: Targeting tyrosine kinases in cancer: the second wave. Science. 312:1175–1178. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Bianco R, Troiani T, Tortora G and Ciardiello F: Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer. 12(Suppl 1): S159–S171. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 107:1207–1218. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Benavente S, Huang S, Armstrong EA, et al: Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res. 15:1585–1592. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Di Lorenzo G, Tortora G, D’Armiento FP, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 8:3438–3444. 2002.PubMed/NCBI
21.	Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5:280–285. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Soler M, Mancini F, Meca-Cortes O, et al: HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer. 125:2565–2575. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Ricciardelli C, Jackson MW, Choong CS, et al: Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate. 68:830–838. 2008. View Article : Google Scholar
24.	Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A and Bologna M: Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol. 129:165–174. 2003.
25.	Dhupkar P, Dowling M, Cengel K and Chen B: Effects of anti-EGFR antibody cetuximab on androgen-independent prostate cancer cells. Anticancer Res. 30:1905–1910. 2010.PubMed/NCBI
26.	Festuccia C, Gravina GL, Biordi L, et al: Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate. 69:1529–1537. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Canil CM, Moore MJ, Winquist E, et al: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 23:455–460. 2005. View Article : Google Scholar
28.	Gravis G, Bladou F, Salem N, et al: Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol. 19:1624–1628. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Wilding G, Soulie P, Trump D, Das-Gupta A and Small E: Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 106:1917–1924. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Ziada A, Barqawi A, Glode LM, et al: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 60:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Whang YE, Armstrong AJ, Rathmell WK, et al: A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol. Mar 9–2011.(Epub ahead of print).
32.	Sridhar SS, Hotte SJ, Chin JL, et al: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol. 33:609–613. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Nabhan C, Lestingi TM, Galvez A, et al: Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial. Urology. 74:665–671. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Yotsumoto F, Yagi H, Suzuki SO, et al: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun. 365:555–561. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med. 20:3–10. 2007.
36.	Li C, Iida M, Dunn EF, Ghia AJ and Wheeler DL: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 28:3801–3813. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Ritter CA, Perez-Torres M, Rinehart C, et al: Human breast cancer cells selected for resistance to trastuzumab in vivo over-express epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 13:4909–4919. 2007. View Article : Google Scholar
38.	Hutcheson IR, Knowlden JM, Hiscox SE, et al: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 9:R502007. View Article : Google Scholar : PubMed/NCBI
39.	Kong A, Calleja V, Leboucher P, Harris A, Parker PJ and Larijani B: HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One. 3:e28812008. View Article : Google Scholar : PubMed/NCBI
40.	Amin DN, Campbell MR and Moasser MM: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 21:944–950. 2010. View Article : Google Scholar : PubMed/NCBI
41.	Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
42.	Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Mendelsohn J: Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother. 52:342–346. 2003.PubMed/NCBI
44.	Pinkas-Kramarski R, Lenferink AE, Bacus SS, et al: The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene. 16:1249–1258. 1998. View Article : Google Scholar : PubMed/NCBI
45.	Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A and Pandiella A: Neuregulins and cancer. Clin Cancer Res. 14:3237–3241. 2008. View Article : Google Scholar : PubMed/NCBI
46.	Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C and Parry G: EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat. 122:685–697. 2010. View Article : Google Scholar : PubMed/NCBI
47.	Festuccia C, Angelucci A, Gravina GL, et al: Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost. 93:964–975. 2005.
48.	Viloria-Petit AM and Kerbel RS: Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys. 58:914–926. 2004. View Article : Google Scholar : PubMed/NCBI
49.	Koutsopoulos AV, Mavroudis D, Dambaki KI, et al: Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer. 57:193–200. 2007. View Article : Google Scholar : PubMed/NCBI
50.	Onn A, Correa AM, Gilcrease M, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 10:136–143. 2004. View Article : Google Scholar : PubMed/NCBI
51.	Chow NH, Chan SH, Tzai TS, Ho CL and Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 7:1957–1962. 2001.PubMed/NCBI
52.	Wiseman SM, Makretsov N, Nielsen TO, et al: Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103:1770–1777. 2005. View Article : Google Scholar : PubMed/NCBI
53.	Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori. 90:2–8. 2004.PubMed/NCBI
54.	Festuccia C, Muzi P, Millimaggi D, et al: Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer. 12:983–998. 2005. View Article : Google Scholar : PubMed/NCBI
55.	Wang G, Reed E and Li QQ: Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med. 14:23–34. 2004.PubMed/NCBI
56.	Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ and Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58:2720–2723. 1998.PubMed/NCBI
57.	Zhu Z, Kleeff J, Friess H, et al: Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun. 273:1019–1024. 2000. View Article : Google Scholar : PubMed/NCBI
58.	Torring N, Jorgensen PE, Sorensen BS and Nexo E: Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res. 20:91–95. 2000.PubMed/NCBI
59.	Torring N, Hansen FD, Sorensen BS, Orntoft TF and Nexo E: Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Prostate. 64:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
60.	Gupta GP, Nguyen DX, Chiang AC, et al: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 446:765–770. 2007. View Article : Google Scholar : PubMed/NCBI
61.	Watanabe T, Kobunai T, Yamamoto Y, et al: Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer. 46:2119–2126. 2010. View Article : Google Scholar
62.	Oliveras-Ferraros C, Vall-Llovera AM, Salip DC, et al: Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs. 30:846–852. 2012. View Article : Google Scholar : PubMed/NCBI
63.	Baker JB, Dutta D, Watson D, et al: Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer. 104:488–495. 2011. View Article : Google Scholar : PubMed/NCBI
64.	Ben-Yosef R, Starr A, Karaush V, et al: ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate. 67:871–880. 2007. View Article : Google Scholar : PubMed/NCBI
65.	Vexler A, Lidawi G, Loew V, et al: Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies. Cancer Biol Ther. 7:1090–1094. 2008.PubMed/NCBI
66.	Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B and Bartlett JM: The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res. 12:123–130. 2006. View Article : Google Scholar : PubMed/NCBI
67.	Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin. 59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
68.	De Alava E, Ocana A, Abad M, et al: Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol. 25:2656–2663. 2007.PubMed/NCBI
69.	Motoyama AB, Hynes NE and Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62:3151–3158. 2002.PubMed/NCBI
70.	Normanno N, De Luca A, Maiello MR, et al: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 207:420–427. 2006. View Article : Google Scholar : PubMed/NCBI